IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer
Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter
Valeura Energy: Positioned for Organic Growth and Accretive M&A in Southeast Asia’s Offshore Oil Sector
